Company Filing History:
Years Active: 2009-2011
Title: Roman Lenarsic: Innovator in Pharmaceutical Chemistry
Introduction
Roman Lenarsic, a distinguished inventor based in Ljubljana, Slovenia, has made significant contributions to the field of pharmaceutical chemistry. With two patents to his name, he has demonstrated exceptional skill and innovation in developing novel drug formulations.
Latest Patents
Lenarsic's most recent patents focus on olanzapine, an antipsychotic medication. The first patent, "Isopropanol Water Solvate of Olanzapine," introduces a unique solvated form of olanzapine that incorporates two molecules of water and one molecule of isopropanol per two molecules of the drug. This formulation not only offers an innovative approach to the medication but also highlights potential pathways for converting into other forms of olanzapine, specifically form (I), along with processes for its preparation.
His second patent, "Process and Intermediates for the Preparation of Olanzapine," presents an improved methodology for synthesizing olanzapine, including the development of essential intermediates that enhance the efficiency and efficacy of the production process.
Career Highlights
Roman Lenarsic is affiliated with Krka, Tovarna Zdravil, D.d., a well-regarded pharmaceutical company known for its focus on research and development of innovative medicines. His work at Krka has been pivotal in advancing their product offerings in the competitive pharmaceutical landscape.
Collaborations
In his journey as an inventor, Lenarsic has partnered with talented colleagues such as Rok Zupet and Milena Benedik. Together, they have collaborated on projects that leverage their collective expertise to bring innovative solutions to complex pharmaceutical challenges.
Conclusion
Roman Lenarsic stands out as an inventive force in the pharmaceutical industry. His recent patents illustrate not only his dedication to improving drug formulations but also his ability to collaborate effectively with others in his field. As he continues his work at Krka, his contributions are likely to play a significant role in the future of pharmaceutical innovations.